Publications

Selected Publications:

  • 108. Gelinas AD, Davies DR, Janjic N. Embracing proteins: structural themes in aptamer-protein complexes. Current Opinion in Structural Biology 2016, 36: 122-132. Pubmed
  • 107. Gillespie JJ, Phan IQ, Scheib H, Subramanian S, Edwards TE, Lehman SS, Piitulainen H, Sayeedur Rahman M, Rennoll-Bankert KE, Staker BL, Taira S, Stacy R, Myler PJ, Azad AF, Pulliainen AT. Structural insight into how bacteria prevent interference between multiple divergent type IV secretion systems. MBio 2015, 8, e01867-15. Pubmed
  • 106. Klumpp K, Lam AM, Lukacs C, Vogel R, Ren S, Espirtu C, Baydo R, Atkins K, Abendroth J, Liao G, Efimov A, Hartman G, Flores OA. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. PNAS, 2015, 112, 15196-15201. Pubmed
  • 105. Oliva Chavez AS, Fairman JW, Felsheim RF, Nelson CM, Herron MJ, Higgins L, Burkhardt NY, Oliver JD, Markowski TW, Kurtti TJ, Edwards TE, Munderloh UG. PLoS Pathogens, 2015, 11, e1005248. Pubmed
  • 105. Kryshtafovych A, Moult J, Basle A, Burgin A, Craig TK, Edwards RA, Fass D, Hartmann MD, Korycinski M, Lewis RJ, Lorimer D, Lupas AN, Newman J, Peat TS, Piepenbrink KH, Prahlad J, van Raaij MJ, Rower F, Segall AM, Seguritan V, Sundberg EJ, Singh AK, Wilson MA, Schwede T. Some of the most interesting CASP11 targets through the eyes of the authors. Proteins, 2015. Pubmed
  • 104. Jarvis TC, Davies DD, Hisaminato A, Resnicow DI, Gupta S, Waugh SM, Nagabukuro A, Wadatsu T, Hishigaki H, Gawande B, Zhang C, Wolk SK, Mayfield WS, Nakaishi Y, Burgin AB, Stewart LJ, Edwards TE, Gelinas AD, Schneider DJ, Janjic N. Non-helical DNA triplex forms a unique aptamer scaffold for high affinity recognition of nerve growth factor. Structure, 2015, 23, 1293-12304. Pubmed
  • 103. Phan IQ, Davies DR, Moretti NS, Shanmugam D, Cestari I, Anupama A, Fairman JW, Edwards TE, Stuart K, Schenkman S, Myler PJ. Iron superoxide dismutases in eukaryotic pathogens: new insights from Apicomplexa and Trypanosoma structures. Acta Cryst 2015 F71, 615-621. Pubmed
  • 102. Clifton MC, Bruhn JF, Atkins K, Webb TL, Baydo RO, Raymond A, Lorimer DD, Edwards TE, Myler PJ, Saphire EO. High-resolution crystal structure of dimeric VP40 from sudan ebolavirus. J Infect Dis. 2015, 212, S167-S171. Pubmed
  • 101. Buchko GW, Edwards TE, Hewitt SN, Phan IQ, Van Voorhis WC, Miller SI, Myler PJ. Backbone chemical shift assignments for the sensor domain of the Burkholderia pseudomallei histidine kinase RisS: “missing” resonances at the dimer interface. Biomol NMR Assign. 2015, 9, 381-385. Pubmed
  • 100. Moen SO, Fairman JW, Barnes SR, Sullivan A, Nakazawa-Hewitt S, Van Voorhis WC, Staker BL, Lorimer DD, Myler PJ, Edwards TE. Structures of prostaglandin F synthase form the protozoa Leishmania major and Trypanosoma cruzi with NADP. Acta Cryst 2015, F71, 609-614. Pubmed
  • 99. Serbzhinskiy DA, Clifton MC, Sankaran B, Staker BL, Edwards TE, Myler PJ. Structure of an ADP-ribosylation factor, ARF1, from Entamoeba histolytica bound to Mg2+-GDP. Acta Cryst, 2015, F71, 594-599. Pubmed
  • 98. Lorimer DD, Choi R, Abramov A, Nakazawa Hewitt S, Gardberg AS, Van Vorrhis WC, Staker BL, Myler PJ, Edwards TE. Structures of a histidine triad family protein from Entamoeba histolytica bound to sulfate, AMP and GMP. Acta Cryst 2015, F71, 572-576. Pubmed
  • 97. Abendroth J, Choi R, Wall A, Clifton MC, Lukacs CM, Staker BL, Van Voorhis W, Myler P, Lorimer DD, Edwards TE. Structures of aspartate aminotransferases from Trypanosoma brucei, Leishmania major and Giardia lamblia. Acta Cryst, 2015, F71, 566-571. Pubmed
  • 96. Edwards TE, Gardberg AS, Phan IQ, Zhang Y, Staker BL, Myler PJ, Lorimer DD. Structure of uridine diphosphate N-acetylglucosamine pyrophosphate from Entamoeba histolytica. Acta Cryst, 2015, F71, 560-565. Pubmed
  • 95. Buckho GW, Abendroth J, Clifton MC, Robinson H, Zhang Y, Hewitt SN, Staker BL, Edwards TE, Van Voorhis WC, Myler PJ. Structure of a CutA1 divalent-cation tolerance protein from Cryptosporidium parvum, the protozoal parasite responsible for cryptosporidiosis. Acta Cryst, 2015, F71, 522-530. Pubmed
  • 94. Clifton MC, Dranow DM, Leed A, Fulroth B, Fairman JW, Abendroth J, Atkins KA, Wallace E, Fan D, Xu G, Ni ZJ, Daniels D, Van Drie J, Wei G, Burgin AB, Golub TR, Hubbard BK, Serrano-Wu MH. A maltose-binding protein fusion construct yields a robust crystallography platform for MCL1. PLoS One, 2015, 10, e0125010. Pubmed
  • 93. Edwards TE, Baugh L, Bullen J, Baydo RO, Witte P, Thompkins K, Phan IQ, Abendroth J, Clifton MC, Sankaran B, Van Voorhis WC, Myler PJ, Staker BL, Grundner C, Lorimer DD. Crystal structures of Mycobacterial MeaB and MMAA-like GTPases. J Struct Func Genomics, 2015, 16, 91-99. Pubmed
  • 92. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem, 2015, 58, 3682-3692. Pubmed
  • 91. Appleby TC, Perry JK, Murakami E, Barauskas O, Feng J, Cho A, Fox D 3rd, Wetmore DR, McGrath ME, Ray AS, Sofia MJ, Swaminathan S, Edwards TE. Structural basis for RNA replication by the hepatitis C virus polymerase. Science, 2015, 347, 771-775. Pubmed
  • 90. Baugh L, Phan I, Begley DW, Clifton MC, Armour B, Dranow DM, Taylor BM, Muruthi MM, Abendroth J, Fairman JW, Fox D 3rd, Dieterich SH, Staker BL, Gardberg AS, Choi R, Hewitt SN, Napuli AL, Myers S, Barrett LK, Zhang Y, Ferrell M, Mundt E, Thompkins K, Tran N, Lyons-Abbott S, Abramov A, Sekar A, Serbzhinskiy D, Lorimer D, Stacy R, Stewart LJ, Edwards TE, Van Voorhis WC, Myler PJ. Increasing the structural coverage of tuberculosis drug targets. Tuberculosis, 2015, 95, 142-148. Pubmed
  • 89. Moreno MA, Alonso A, Alcolea PJ, Abramov A, de Lacoba MG, Abendroth J, Zhang S, Edwards T, Lorimer D, Myler PJ, Larraga V. Tyrosine aminotransferase from Leishmania infantum: a new drug target candidate. Int J Parasitol Drugs Drug Resist. 2014, 4, 347-354. Pubmed
  • 88. Fang C, D’Souza B, Thompson CF, Clifton MC, Fairman JW, Fulroth B, Leed A, McCarren P, Wang L, Wang Y, Feau C, Kaushik VK, Palmer M, Wei G, Golub TR, Hubbard BK, Serrano-Wu MH. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Med. Chem. Lett. 2014, 5, 1308-1312. Pubmed
  • 87. Aoyagi-Scharber M, Gardberg AS, Yip BK, Wang B, Shen Y, Fitzpatrick PA. Structural basis for the inhibition of poly(ADP-ribose) polymerase 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2014, 70, 1143-1149. Pubmed
  • 86. Lam AM, Edwards TE, Mosley RT, Murakami E, Bansal S, Lugo C, Bao H, Otto MJ, Sofia MJ, Furman PA. Molecular and structural basis for the roles of Hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance. Antimicrob. Agents Chemother. 2014, 58(11), 6861-6869. Pubmed
  • 85. Moen SO, Abendroth J, Fairman JW, Baydo RO, Bullen J, Kirkwood JL, Barnes SR, Raymond AC, Begley DW, Henkel G, McCormack K, Tam VC, Phan I, Staker BL, Stacy R, Myler PJ, Lorimer D, Edwards TE. Sci. Rep. 2014, 4, 5944. Pubmed
  • 84. Terry-Lorenzo RT, Chun LE, Brown SP, Heffernan ML, Fang QK, Orsini MA, Pollegioni L, Hardy LW, Spear KL, Large TH. Novel human D-amino acid oxidase inhibitors stabilize an active site lip open conformation. Biosci. Rep. 2014, 34(4), e00133. Pubmed
  • 83. Hagen TJ, Mo X, Burgin AB, Fox D 3rd, Zhang Z, Gurney ME. Discovery of triazines as selective PDE4B versus PDE4D inhibitors. Bioorg. Med. Chem. Lett. 2014, 24(16), 4031-4034. Pubmed
  • 82. Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, Conley GP, Chen J, Viswanathan M, Kastrapeli N, Cosic J, Mason S, DiLeo M, Abendroth J, Kuzmic P, Ladner RC, Edwards TE, TenHoor C, Adelman BA, Nixon AE, Sexton DJ. Inhibition of plasma kallikrein by a highly specific, active site blocking antibody. J. Biol. Chem. 2014, 289(34), 23596-23608. Pubmed
  • 81. Moreno MA, Abramov A, Abendroth J, Alonso A, Zhang S, Alcolea PJ, Edwards T, Lorimer D, Myler PJ, Larraga V. Structure of tyrosine aminotransferase from Leishmania infantum. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2014, 70, 583-587. Pubmed
  • 80. Clifton MC, Kirchdoerfer RN, Atkins K, Abendroth J, Raymond A, Grice R, Barnes S, Moen S, Lorimer D, Edwards TE, Myler PJ, Saphire EO. Structure of the Reston ebolavirus VP30 C-terminal domain. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2014, 70, 457-460. Pubmed
  • 79. Davies D.R. Screening Ligands by X-ray Crystallography. Methods Mol Biol. 2014, 1140, 315-323. Pubmed
  • 78. Linford A.S., Jiang N.M., Edwards T.E., Sherman N.E., Van Voorhis W.C., Stewart L.J., Myler P.J., Staker B.L., Petri W.A. Jr. Crystal structure and putative substrate identification for the Entamoeba histolytica low molecular weight tyrosine phosphatase. Mol Biochem Parasitol. 2014, 193, 33-44. Pubmed
  • 77. Gelinas A.D., Davies D.R., Edwards T.E., Rohloff J.C., Carter J.D., Zhang C., Gupta S., Ishikawa Y., Hirota M., Nakaishi Y., Jarvis T.C., Janjic N. Crystal structure of interleukin-6 in complex with a modified nucleic acid ligand. J. Biol. Chem. 2014, 289, 8720-8734. Pubmed
  • 76. Begley D.W., Moen S.O., Pierce P.G., Zartler E.R. Saturation transfer difference NMR for fragment screening. Curr. Protoc. Chem. Biol. 2013, 5, 251-68. Pubmed
  • 75. Begley D.W., Fox D. 3rd, Jenner D., Juli C., Pierce P.G., Abendroth J., Muruthi M., Safford K., Anderson V., Atkins K., Barnes S.R., Moen S.O., Raymond A.C., Stacy R., Myler P.J., Staker B.L., Harmer N.J., Norville I.H., Holzgrabe U., Sarkar-Tyson M., Edwards T.E., Lorimer D. A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins. Antimicrob. Agents Chemother. 2014, 58, 1458-1467. Pubmed
  • 74. Fox D. 3rd, Burgin A.B., Gurney M.E. Structural basis for the design of selective phosphodiesterase 4B inhibitors. Cell Signal. 2013, 6, 657-663. Pubmed
  • 73. Abendroth J., Ollodart A., Andrew E.S., Myler P.J., Staker B.L., Edwards T.E., Arcus V.L., Grundner C. Mycobacterium tuberculosis Rv2179c establishes a new exoribonuclease family with broad phylogenetic distribution. J. Biol. Chem. 2014, 289, 2139-2147. Pubmed
  • 72. Zhang Z., Jakkaraju S., Blain J., Gogol J., Zhao L., Hartley R.C., Karlsson C.A., Staker B.L., Edwards T.E., Stewart L.J., Myler P.J., Clare M., Begley D.W., Horn J.R., Hagen T.J. Cytidine derivatives a IspF inhibitors of Burkholderia psuedomallei. Bioorg Med. Chem. Lett. 2013, 23, 6860-6863. Pubmed
  • 71. Armour B.L., Barnes S.R., Moen S.O., Smith E., Raymond A.C., Fairman J.W., Stewart L.J., Staker B.L., Begley D.W., Edwards T.E., Lorimer D. Multi-target parallel processing approaches for gene-to-structure determination of the influenza polymerase PB2 subunit. J. Vis. Exp. 2013. Pubmed
  • 70. Bodeci A., Fabrini R., Farrotti A., Stella L., Ketterman A.J., Pedersen J.Z., Allocati N., Lau P.C., Grosse S., Eltis L.D., Ruzzini A., Edwards T.E., Morici L., Del Grosso E., Guidoni L., Bovi D., Lo Bello M., Federici G., Parker M.W., Board P.G., Ricci G. The impact of nitric oxide toxicity on the evolution of the glutathione transferase superfamily: a proposal for an evolutionary driving force. J. Biol. Chem. 2013, 288, 936-24, 947. Pubmed
  • 69. Buchko G.W., Abendroth J., Robinson H., Zhang Y., Hewitt S.N., Edwards T.E., Van Voorhis W.C., Myler P.J. Crystal structure of a macrophage migration inhibitory factor from Giardia lamblia. J. Struct. Func. Genomics 2013, 14, 47-57. Pubmed
  • 68. Zhang Y., Gardberg A., Edwards T.E., Sankaran B., Robinson H., Varnum S.M., Buchko G.W. Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D. Biochimie. 2013, 95, 1379-1385. Pubmed
  • 67. Frank J.A., Lorimer D., Youle M., Witte P., Craig T., Abendroth J., Rohwer F., Edwards R.A., Segall A.M., Burgin A.B. Jr. Structure and function of a cyanophage-encoded peptide deformylase. ISME J. 2013, 7, 1150-1160. Pubmed
  • 66. Baugh L., Gallagher L.A., Patrapuvich R., Clifton M.C., Gardberg A.S., Edwards T.E., Armour B., Begley D.W., Dieterich S.H., Dranow D.M., Abendroth J., Fairman J.W., Fox D. 3rd, Staker B.L., Phan I., Gillespie A., Choi R., Nakazawa-Hewitt S., Nguyen M.T., Napuli A., Barrett L., Buchko G.W., Stacy R., Myler P.J., Stewart L.J., Manoil C., Van Voorhis W.C. Combining functional and structural genomics to sample the essential burkholderia structome. PLoS One. 2013, 8, e53851. Pubmed
  • 65. Davies D.R., Gelinas A.D., Zhang C., Rohloff J.C., Carter J.D., O’Connell D., Waugh S.M., Wolk S.K., Mayfield W.S., Burgin A.B., Edwards T.E., Stewart L.J., Gold L., Janjic N., Jarvis T.C. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci U S A, 2012. 109, 19971-19976. Pubmed
  • 64. Seguritan V., Alves N. Jr., Arnoult M., Raymond A., Lorimer D., Burgin A.B. Jr., Salamon P., Segall A.M. Artificial neural networks trained to detect viral and phage structural proteins. PLoS Comput Biol. 2012 , 8, e1002657. Pubmed
  • 63. Edwards T.E., Liao R., Phan I., Myler P.J., Grundner C. Mycobacterium thermoresistibile as a source of thermostable orthologs of Mycobacterium tuberculosis proteins. Protein Sci. 2012 21, 1093-1096. Pubmed
  • 62. Mosley R.T., Edwards T.E., Murakami E., Lam A.M., Grice R.L., Du J., Sofia M.J., Furman P.A., Otto M.J. Structure of HCV Polymerase in Complex with Primer-Template RNA. J. Virol. 2012, 86, 6503-6511. Pubmed
  • 61. Green L.S., Chun L.E., Patton A.K., Sun X., Rosenthal G.J., Richards J.P. Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting S-Nitrosoglutathione Reductase. Biochemistry. 2012, 10, 2157-68. Pubmed
  • 60. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., Kim M.K., Beaven M.A., Burgin A.B., Manganiello V., Chung J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012, 148, 421-33. Pubmed
  • 59. Abendroth J., Gardberg A.S., Robinson J.I., Christensen J.S., Staker B.L., Myler P.J.,Stewart L.J., Edwards T.E. SAD phasing using iodide ions in a high-throughput structural genomics environment. J Struct Funct Genomics. 2011, 12, 83-95. Pubmed
  • 58. Begley D.W., Davies D.R., Hartley R.C., Edwards T.E., Staker B.L., Van Voorhis W.C., Myler P.J., Stewart L.J. Fragment screening of infectious disease targets in a structural genomics environment. Methods Enzymol. 2011, 493, 533-56. Pubmed
  • 57. Sun X., Wasley J.W.F., Qiu J., Blonder J.P., Stout A.M., Green L.S., Strong S.A., Colagiovanni D.B., Richards J.P., Mutka S.C., Chun L., Rosenthal G.J. Discovery of S-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory disease. ACS Med. Chem. Lett. 2011, 2, 402-406. Pubmed
  • 56. Chan W.W., Wise S.C., Kaufman M.D., Ahn Y.M., Ensinger C.L., Haack T., Hood M.M., Jones J., Lord J.W., Lu W.P., Miller D., Patt W.C., Smith B.D., Petillo P.A., Rutkoski T.J., Telikepalli H., Vogeti L., Yao T., Chun L., Clark R., Evangelista P., Gavrilescu L.C., Lazarides K., Zaleskas V.M., Stewart L.J., Van Etten R.A., Flynn D.L. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19, 556-68. Pubmed
  • 55. Davies D.R., Begley D.W., Hartley R.C., Staker B.L., Stewart L.J. Predicting the success of fragment screening by X-ray crystallography. Methods Enzymol.2011, 492, 91-114. Pubmed
  • 54. Di Paolo J.A., Huang T., Balazs M., Barbosa J., Barck K.H., Bravo B.J., Carano R.A., Darrow J., Davies D.R., DeForge L.E., Diehl L., Ferrando R., Gallion S.L., Giannetti A.M., Gribling P., Hurez V., Hymowitz S.G., Jones R., Kropf J.E., Lee W.P., Maciejewski P.M., Mitchell S.A., Rong H., Staker B.L., Whitney J.A., Yeh S., Young W.B., Yu C., Zhang J., Reif K., Currie K.S. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011, 7, 41-50. Pubmed
  • 53. Edwards T.E., Bryan C.M., Leibly D.J., Dieterich S.H., Abendroth J., Sankaran B., Sivam D., Staker B.L., Van Voorhis W.C., Myler P.J., Stewart L.J. Structures of a putative _-class glutathione S-transferase from the pathogenic fungus Coccidioides immitis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011, 67,1038-43. Pubmed
  • 52. Edwards T.E., Cekan P., Reginsson G.W., Shelke S.A., Ferré-D’Amaré A.R., Schiemann O., Sigurdsson S.T. Crystal structure of a DNA containing the planar,phenoxazine-derived bi-functional spectroscopic probe C. Nucleic Acids Res. 2011, 39, 4419-26. Pubmed
  • 51. Gurney M.E., Burgin A.B., Magnusson O.T., Stewart L.J. Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol. 2011, 204, 167-92. Pubmed
  • 50. Jaffe E.K., Shanmugam D., Gardberg A., Dieterich S., Sankaran B., Stewart L.J., Myler P.J., Roos D.S. Crystal structure of Toxoplasma gondii porphobilinogen synthase: insights on octameric structure and porphobilinogen formation. J Biol Chem. 2011, 287, 15298-307. Pubmed
  • 49. Stacy R., Begley D.W., Phan I., Staker B.L., Van Voorhis W.C., Varani G., Buchko G.W., Stewart L.J., Myler P.J. Structural genomics of infectious disease drug targets: the SSGCID. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011, 67, 979-984. Pubmed
  • 48. Pitts S.L., Liou G.F., Mitchenall L.A., Burgin A.B., Maxwell A., Neuman K.C., Osheroff N. Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Nucleic Acids Res. 2011, 39, 4808-17. Pubmed
  • 47. Sun X., Qiu J., Strong S.A., Green L.S., Wasley J.W., Colagiovanni D.B., Mutka S.C., Blonder J.P., Stout A.M., Richards J.P., Chun L., Rosenthal G.J. Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement. Bioorg Med Chem Lett. 2011, 21, 3671-5. Pubmed
  • 46. Wallace E., Dranow D., Laible P.D., Christensen J., Nollert P. Monoolein lipidphases as incorporation and enrichment materials for membrane protein crystallization. PLoS One. 2011, 6, e24488. Pubmed
  • 45. Yates S.P., Edwards T.E., Bryan C.M., Stein A.J., Van Voorhis W.C., Myler P.J., Stewart L.J., Zheng J., Jia Z. Structural basis of the substrate specificity of bifunctional isocitrate dehydrogenase kinase/phosphatase. Biochemistry. 2011, 50, 8103-6. Pubmed
  • 44. Abendroth J., McCormick M.S., Edwards T.E., Staker B., Loewen R., Gifford M., Rifkin J., Mayer C., Guo W., Zhang Y., Myler P., Kelley A., Analau E., Hewitt S.N., Napuli A.J.,Kuhn P., Ruth R.D., Stewart L.J. X-ray structure determination of the glycinecleavage system protein H of Mycobacterium tuberculosis using an inverse Compton synchrotron X-ray source. J Struct Funct Genomics. 2010, 11, 91-100. Pubmed
  • 43. Abendroth J., McCormick M.S., Edwards T.E., Staker B., Loewen R., Gifford M., Rifkin J., Mayer C., Guo W., Zhang Y., Myler P., Kelley A., Analau E., Hewitt S.N., Napuli A.J., Kuhn P., Ruth R.D., Stewart L.J. X-ray structure determination of the glycine cleavage system protein H of Mycobacterium tuberculosis using an inverse Compton synchrotron X-ray source. J Struct Funct Genomics. 2010, 11, 91-100. Pubmed
  • 42. Ahn Y.M., Clare M., Ensinger C.L., Hood M.M., Lord J.W., Lu W.P., Miller D.F., Patt W.C., Smith B.D., Vogeti L., Kaufman M.D., Petillo P.A., Wise S.C., Abendroth J., Chun L., Clark R., Feese M., Kim H., Stewart L., Flynn D.L. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorg Med Chem Lett. 2010, 20, 5793-8. Pubmed
  • 41. Ameriks M.K., Bembenek S.D., Burdett M.T., Choong I.C., Edwards J.P., Gebauer D., Gu Y., Karlsson L., Purkey H.E., Staker B.L., Sun S., Thurmond R.L., Zhu J. Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors. Bioorg Med Chem Lett. 2010, 20, 4060-4. Pubmed
  • 40. Brelidze T.I., Carlson A.E., Davies D.R., Stewart L.J., Zagotta W.N. Identifying regulators for EAG1 channels with a novel electrophysiology and tryptophanfluorescence based screen. PLoS One. 2010, 5, pii: e12523. Pubmed
  • 39. Burgin A.B., Magnusson O.T., Singh J., Witte P., Staker B.L., Bjornsson J.M.,Thorsteinsdottir M., Hrafnsdottir S., Hagen T., Kiselyov A.S., Stewart L.J., Gurney M.E. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010, 28, 63-70. Pubmed
  • 38. Davies D.R., Mamat B., Magnusson O.T., Christensen J., Haraldsson M.H., Mishra R., Pease B., Hansen E., Singh J., Zembower D., Kim H., Kiselyov A.S., Burgin A.B., Gurney M.E., Stewart L.J. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem. 2009, 52, 4694-715. Erratumin: J Med Chem. 2010, 53, 2330-1. Pubmed
  • 37. Edwards T.E., Phan I., Abendroth J., Dieterich S.H., Masoudi A., Guo W., Hewitt S.N., Kelley A., Leibly D., Brittnacher M.J., Staker B.L., Miller S.I., Van Voorhis W.C., Myler P.J., Stewart L.J. Structure of a Burkholderia pseudomallei trimeric autotransporter adhesin head. PLoS One. 2010, 5, pii: e12803. Pubmed
  • 36. Gerdts C.J., Stahl G.L., Napuli A., Staker B., Abendroth J., Edwards T.E., Myler P., Van Voorhis W., Nollert P., Stewart L.J. Nanovolume optimization of protein crystal growth using the microcapillary protein crystallization system. J Appl Crystallogr. 2010, 43, 1078-1083. Pubmed
  • 35. Sandanayaka V., Mamat B., Mishra R.K., Winger J., Krohn M., Zhou L.M., Keyvan M., Enache L., Sullins D., Onua E., Zhang J., Halldorsdottir G., Sigthorsdottir H., Thorlaksdottir A., Sigthorsson G., Thorsteinnsdottir M., Davies D.R., Stewart L.J., Zembower D.E., Andresson T., Kiselyov A.S., Singh J., Gurney M.E. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem. 2010, 53, 573-85. Pubmed
  • 34. Schmidt B.H., Burgin A.B., Deweese J.E., Osheroff N., Berger J.M. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature. 2010, 465, 641-4. Pubmed
  • 33. Yamada S., Hatta M., Staker B.L., Watanabe S., Imai M., Shinya K., Sakai-Tagawa Y., Ito M., Ozawa M., Watanabe T., Sakabe S., Li C., Kim J.H., Myler P.J., Phan I., Raymond A., Smith E., Stacy R., Nidom C.A., Lank S.M., Wiseman R.W., Bimber B.N., O’Connor D.H., Neumann G., Stewart L.J., Kawaoka Y. Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog. 2010, 6, e1001034. Pubmed
  • 32. Deweese J.E., Burch A.M., Burgin A.B., Osheroff N. Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases. Biochemistry. 2009, 48, 1862-9. Pubmed
  • 31. Deweese J.E., Guengerich F.P., Burgin A.B., Osheroff N. Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase II alpha. Biochemistry. 2009, 48, 8940-7. Pubmed
  • 30. Lorimer D., Raymond A., Walchli J., Mixon M., Barrow A., Wallace E., Grice R., Burgin A., Stewart L. Gene composer: database software for protein construct design, codon engineering, and gene synthesis. BMC Biotechnol. 2009, 9, 36. Pubmed
  • 29. Myler P.J., Stacy R., Stewart L., Staker B.L., Van Voorhis W.C., Varani G., Buchko G.W. The Seattle Structural Genomics Center for Infectious Disease (SSGCID). Infect Disord Drug Targets. 2009, 9, 493-506. Pubmed
  • 28. Raymond A., Lovell S., Lorimer D., Walchli J., Mixon M., Wallace E., Thompkins K., Archer K., Burgin A., Stewart L. Combined protein construct and synthetic gene engineering for heterologous protein expression and crystallization using Gene Composer. BMC Biotechnol. 2009, 9, 37. Pubmed
  • 27. Van Voorhis W.C., Hol W.G., Myler P.J., Stewart LJ. The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol. 2009, 5, e1000530. Pubmed
  • 26. Deweese J.E., Burgin A.B., Osheroff N. Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res. 2008, 36,4883-93. Pubmed
  • 25. Deweese J.E., Burgin A.B., Osheroff N. Using 3′-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha. Biochemistry. 2008, 47, 4129-40. Pubmed
  • 24. Singh J., Salcius M., Liu S.W., Staker B.L., Mishra R., Thurmond J., Michaud G., Mattoon D.R., Printen J., Christensen J., Bjornsson J.M., Pollok B.A., Kiledjian M., Stewart L., Jarecki J., Gurney M.E. DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem Biol. 2008, 3, 711-22. Pubmed
  • 23. Evans R.J., Davies D.R., Bullard J.M., Christensen J., Green L.S., Guiles J.W., Pata J.D., Ribble W.K., Janjic N., Jarvis T.C. Structure of PolC reveals unique DNA binding and fidelity determinants. Proc Natl Acad Sci U S A. 2008, 105, 20695-700. Pubmed
  • 22. Marchand C., Antony S., Kohn K.W., Cushman M., Ioanoviciu A., Staker B.L., Burgin A.B., Stewart L., Pommier Y. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther. 2006, 5, 287-95. Pubmed
  • 21. Raymond A.C., Burgin A.B. Jr. Tyrosyl-DNA phosphodiesterase (Tdp1) (3′-phosphotyrosyl DNA phosphodiesterase). Methods Enzymol. 2006, 409, 511-24. Pubmed
  • 20. Kobryn K., Burgin A.B., Chaconas G. Uncoupling the chemical steps of telomere resolution by ResT. J Biol Chem. 2005, 280, 26788-95. Pubmed
  • 19. Nollert P. Membrane protein crystallization in amphiphile phases: practical and theoretical considerations. Prog Biophys Mol Biol. 2005, 88, 339-57. Pubmed
  • 18. Raymond A.C., Staker B.L., Burgin A.B. Jr. Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1). J Biol Chem. 2005, 280, 22029-35. Pubmed
  • 17. Staker B.L., Feese M.D., Cushman M., Pommier Y., Zembower D., Stewart L., Burgin A.B. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem. 2005, 48, 2336-45. Pubmed
  • 16. Bromberg K.D., Vélez-Cruz R., Burgin A.B., Osheroff N. DNA ligation catalyzed by human topoisomerase II alpha. Biochemistry. 2004, 43, 13416-23. Pubmed
  • 15. Chrencik J.E., Staker B.L., Burgin A.B., Pourquier P., Pommier Y., Stewart L., Redinbo M.R. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol. 2004, 339, 773-84. Pubmed
  • 14. Colley W.C., van der Merwe M., Vance J.R., Burgin A.B. Jr., Bjornsti M.A.. Substitution of conserved residues within the active site alters the cleavage relegation equilibrium of DNA topoisomerase I. J Biol Chem. 2004, 279, 54069-78. Pubmed
  • 13. Deneke J., Burgin A.B., Wilson S.L., Chaconas G. Catalytic residues of the telomere resolvase ResT: a pattern similar to, but distinct from, tyrosine recombinases and type IB topoisomerases. J Biol Chem. 2004, 279, 53699-706. Pubmed
  • 12. Nollert P. Lipidic cubic phases as matrices for membrane protein crystallization. Methods. 2004, 34, 348-53. Pubmed
  • 11. Raymond A.C., Rideout M.C., Staker B., Hjerrild K., Burgin A.B. Jr. Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues. J Mol Biol. 2004, 338, 895-906. Pubmed
  • 10. Rideout M.C., Raymond A.C., Burgin A.B. Jr. Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I. Nucleic Acids Res. 2004, 32, 4657-64. Pubmed
  • 9. Bromberg K.D., Burgin A.B., Osheroff N. A two-drug model for etoposide action against human topoisomerase IIalpha. J Biol Chem. 2003, 278, 7406-12. Pubmed
  • 8. Chrencik J.E., Burgin A.B., Pommier Y., Stewart L., Redinbo M.R. Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. J Biol Chem. 2003, 278, 12461-6. Pubmed
  • 7. Fox B.M., Xiao X., Antony S., Kohlhagen G., Pommier Y., Staker B.L., Stewart L., Cushman M. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem. 2003, 46, 3275-82. Pubmed
  • 6. Nollert P. Microscope detection options for colorless protein crystals grown in lipidic cubic phases. J Appl Crystallogr. 2003, 36, 1295-1296. Pubmed
  • 5. Bromberg K.D., Hendricks C., Burgin A.B., Osheroff N. Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5′ covalently activated oligonucleotide substrates to study enzyme mechanism. J Biol Chem. 2002, 277, 1201-6. Pubmed
  • 4. Kazmierczak R.A., Swalla B.M., Burgin AB, Gumport RI, Gardner JF. Regulation of site-specific recombination by the C-terminus of lambda integrase. Nucleic Acids Res. 2002, 30, 5193-204. Pubmed
  • 3. Lesher D.T., Pommier Y., Stewart L., Redinbo MR. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc Natl Acad Sci U S A. 2002, 99, 12102-7. Pubmed
  • 2. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin A.B. Jr., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002, 99, 15387-92. Pubmed
  • 1. Stewart L., Clark R., Behnke C. High-throughput crystallization and structure determination in drug discovery. Drug Discov Today. 2002, 7, 187-96. Pubmed

@2016 Beryllium Discovery Corp – 844-BE4-FOUR | info@be4.com

Terms of Services º Terms of Use